Prostate Cancer Testing Market (Updated Version Available)

The report offers detailed coverage of Prostate Cancer Testing industry and main market trends. Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ultrasound (TRUS)-guided prostate biopsy using a systematic 12-core method.
The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.
There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low. Hence, only few people are capable of affording these drugs. Therefore, because of this high cost, the use of generic drugs is more, and hence, it is hindering the growth of the prostate cancer drugs market.
North America is the leading global market with the largest revenue share in 2020. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region due to the improving healthcare infrastructure and the growing investments by the key market players.
The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Prostate Cancer Testing by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

The report forecast global Prostate Cancer Testing market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2027.

COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Prostate Cancer Testing market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.


First, this report covers the present status and the future prospects of the global Prostate Cancer Testing market for 2015-2027.

Key Companies
Genomic Health
OPKO
Siemens Healthcare
DiaSorin
bioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics


At the same time, we classify Prostate Cancer Testing according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market by Order Type
PSA Tests
CTC Tests
Immunohistochemistry
PCA3 Tests
Others

Market by Application
Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others

Market Segment as follows:
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Prostate Cancer Testing market for the forecast period 2021 - 2027?
• What are the driving forces in the Prostate Cancer Testing market for the forecast period 2021 - 2027?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Prostate Cancer Testing industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?

For any other requirements, please feel free to contact us and we will provide you customized report.